DRS

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Retrieved on: 
Tuesday, March 5, 2024
Senior, Biotechnology, NPV, PMA, Messenger, FDA, Partnership, Marketing, PPV, Food, CRC, AA, Biomarker, Science, Quest Diagnostics, THA, Patient, Clinical trial, Survival, DRS, Colorectal cancer, Gene expression, Medical imaging

In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.

Key Points: 
  • In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.
  • The Company currently commercializes its first-generation test in Europe and in select international territories through its flagship product ColoAlert® via partnerships with third-party laboratories.
  • “Detecting AA lesions allows for early intervention and significantly increases the chance of successful treatment and survival.
  • The study’s primary objectives include calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) in average-risk subjects for CRC and AA.

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

Retrieved on: 
Wednesday, February 28, 2024
Incidence, Virology, LMIC, Vaccine, C1, SME, European, Dyadic, COVID-19, Innovation, Rabies, AVATAR, Disease, DRS, Research, Partnership

The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.

Key Points: 
  • The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.
  • This collaboration seeks to address the global burden of rabies, a disease that annually claims tens of thousands of lives.
  • As per the strategic partnership agreement, Dyadic will receive an equity stake in, fully funded research and development costs, and specified product milestones and royalties upon commercialization.
  • Punt highlighted the potential of combining advances in vaccinology with Dyadic's C1 protein production platform to accelerate research, enhance product development, and lower manufacturing costs.

AOFAS Honors Two Female Orthopaedic Leaders

Retrieved on: 
Tuesday, February 27, 2024
Stamford Hospital, Treace Medical Concepts, Breast cancer, Cancer, Weill Cornell Medicine, Woman, Copy, Ankle, Medical school, Assistant, Physician, Hospital, Female, Fluoroscopy, Surgeon, NewYork-Presbyterian Hospital, Orthopedic surgery, Radiation, Risk, Stanford University, Breast, Prevalence, Operating, Knowledge, New York Medical College, Male, Publication, DRS, Research, Dentistry

“I am proud that AOFAS is making an effort to recognize women in foot and ankle orthopaedic surgery.”

Key Points: 
  • “I am proud that AOFAS is making an effort to recognize women in foot and ankle orthopaedic surgery.”
    Over the past 15 years, Dr. Chou has conducted several research studies to examine breast cancer prevalence among female orthopaedic surgeons.
  • Dr. Chou’s research results confirmed higher breast cancer prevalence among female orthopaedic surgeons than the general population, and in a later study, she discovered higher prevalence among female orthopaedic surgeons compared to women in other surgical specialties.
  • Currently, she is leading a study to evaluate cancer risk associated with radiation exposure in male and female orthopaedic surgeons.
  • I applaud AOFAS for taking that initiative with these awards.”
    Funding for the AOFAS Women’s Leadership Initiative is provided by the Orthopaedic Foot & Ankle Foundation, supported by a grant from Treace Medical Concepts, Inc.

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

Retrieved on: 
Thursday, February 22, 2024
Ophthalmology, Doctor of Philosophy, Quality of life, Diabetic retinopathy, Lead, History, AMD, Patient, Probability, MBBS, DRS, Management

BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced Board of Directors and leadership updates with the addition of Pravin U. Dugel, MD as Executive Chairman and the additions of Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Sanjay Nayak, MBBS, PhD to the Ocular management team as Chief Scientific Officer, Medical Director, and Chief Strategy Officer, respectively. The addition of these four acknowledged strategic and clinical experts puts the Company on track to be a leader in retina care for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other retinal conditions.

Key Points: 
  • The Company also announced that Charles Warden has transitioned from Chairman of the Board to Lead Independent Director.
  • “We are bringing together the ‘Retina Dream Team’ to position Ocular at the forefront of retina care, further energizing the momentum behind the AXPAXLI™ Phase 3 wet AMD program.
  • We believe our expanded leadership team will enable us to potentially accelerate the pace of our clinical program for AXPAXLI™,” said Antony Mattessich, CEO of Ocular Therapeutix.
  • As Ocular moves forward, I am very pleased that Charles will continue his work with the Company as Lead Independent Director.”

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

Retrieved on: 
Thursday, February 22, 2024
ASC, Traumatic brain injury, Inflammation, Quality of life, Neurological disorder, Multiple sclerosis, University, Intellectual disability, Therapy, Neurology, Super Meat Boy, Patient, DSM-IV codes, Clinical trial, Inflammasome, IND, DRS, Research, Pharmaceutical industry

A growing body of evidence supports that activation of more than one type of inflammasome contributes to development of common neurological diseases, and that extracellular ASC specks are involved in disease progression.

Key Points: 
  • A growing body of evidence supports that activation of more than one type of inflammasome contributes to development of common neurological diseases, and that extracellular ASC specks are involved in disease progression.
  • The white paper summarizes the preclinical research of leading inflammasome experts, Drs.
  • The white paper then summarizes data from preclinical research led by Drs.
  • Keane, de Rivero Vaccari, and their colleagues currently have research underway in Parkinson’s disease that was funded through a grant with the Michael J.

Route 92 Medical Announces Completion of Enrollment in the SUMMIT MAX Clinical Trial

Retrieved on: 
Wednesday, February 21, 2024
SAN, Medicine, Ambient occlusion, Randomized controlled trial, Catheter, MD, Principal, FDA, Route, Reperfusion, Safety, Radiology, Patient, Anatomy, Neurosurgery, RCT, DRS, MAX, Brain, Pharmaceutical industry

SAN MATEO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the completion of enrollment in its 250-patient SUMMIT MAX clinical trial ( NCT05018650 ) evaluating the safety and effectiveness of its HiPoint™ 88 and HiPoint 70 Reperfusion Catheters as part of the MonopointⓇ Reperfusion System.

Key Points: 
  • SAN MATEO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the completion of enrollment in its 250-patient SUMMIT MAX clinical trial ( NCT05018650 ) evaluating the safety and effectiveness of its HiPoint™ 88 and HiPoint 70 Reperfusion Catheters as part of the MonopointⓇ Reperfusion System.
  • SUMMIT MAX is the first FDA-approved aspiration thrombectomy trial which is randomized.
  • Randomized controlled trials provide the best clinical science and the SUMMIT MAX Trial compares the Route 92 Medical Monopoint System to the largest commercially available conventional aspiration system.
  • “Route 92 Medical is leading the way in neurovascular innovation technology, bringing clinicians complete solutions designed to improve endovascular thrombectomy procedure times and outcomes.

Foot and Ankle Orthopaedic Surgeons Can Fill the Gap in Barriers to Care for Diabetic Patients

Retrieved on: 
Monday, February 19, 2024
Diabetes, American Diabetes Association, Infection, Ankle, MD, Diabetic foot ulcer, Education, Ulcer, Foot, Surgeon, Risk, Amputation, Hartford, Connecticut, Deformity, Patient, Aronow, Presser foot, DRS, Dentistry

Rosemont, Ill., Feb. 19, 2024 (GLOBE NEWSWIRE) -- Foot and ankle orthopaedic surgeons can help fill the gap in barriers to access to diabetic foot care, according to survey results and presentations at the American Orthopaedic Foot and Ankle Society’s (AOFAS) Winter Meeting last month in Tampa, Florida.

Key Points: 
  • Rosemont, Ill., Feb. 19, 2024 (GLOBE NEWSWIRE) -- Foot and ankle orthopaedic surgeons can help fill the gap in barriers to access to diabetic foot care, according to survey results and presentations at the American Orthopaedic Foot and Ankle Society’s (AOFAS) Winter Meeting last month in Tampa, Florida.
  • The survey results discredited misconceptions that some healthcare professionals and the public may have that orthopaedic surgeons are unable or unwilling to treat diabetic foot diseases.
  • “Foot and ankle orthopaedic surgeons have the expertise and training to treat diabetic foot disease,” Dr. Aronow said.
  • Visit FootCareMD.org to learn more about foot and ankle orthopaedic surgeons and to find one in your area.

Asha Therapeutics to Present at AD/PD™ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year and Welcomes Two New SAB Members

Retrieved on: 
Friday, March 8, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, Other Technology, Research, Software, General Health, Science, Data Management, Clinical Trials, Community health, GSK, AbbVie, Huntington's disease, University, Mathematics, Emory University, Behavioral neurology, Pathology, School, Alzheimer's disease, Johnson & Johnson, Drug design, Gold, Bristol Myers Squibb, Johns Hopkins, Disorder, Psychiatry, Derek, UCB, Computer science, American Neurological Association, Asha, Parkinson's Foundation, Conference, Chemistry, Safety, Amelioration, CNS, Behavioural sciences, Medical school, MD, Neurology, Patient, Florida College, Disease, Publication, DRS, Pharmaceutical industry

Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.

Key Points: 
  • Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.
  • ASHA-091 restores normal mitochondrial function and has demonstrated disease modifying efficacy as a functional cure in preclinical disease models.
  • In preparation for clinical transition, Asha has appointed Dr. Michael Gold and Dr. Allan Levey to their Scientific Advisory Board.
  • Their expertise comes at a pivotal moment for Asha as we transition our first-in-class lead programs designed using our PRISM™ technology to clinical trials.

Signifier Medical Technologies Announces Publication of a New Study Exploring Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea

Retrieved on: 
Thursday, March 7, 2024
Health, Medical Devices, Health Technology, Other Health, General Health, Research, Science, Diabetes, Freedom, CPAP, Patient satisfaction, Sleep apnea, Quality of life, Quality-adjusted life year, Treatment, Obstructive sleep apnea, Continuous positive airway pressure, Technology assessment, ICER, Prevalence, Hypertension, Life imprisonment, PAP, Patient, Canadian International Council, NMES, Signified and signifier, DRS, Health technology

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."

Key Points: 
  • Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."
  • Shan Liu, Jan Pietzsch, and a collaborative research team explores the cost-effectiveness of using neuromuscular electrical stimulation (NMES) as a treatment option for patients with mild obstructive sleep apnea (OSA).
  • The results of the exploratory analysis indicated that neuromuscular electrical stimulation may be a cost-effective treatment option for mild OSA compared to no treatment.
  • "We are excited to see the results of this study reinforce the potential of neuromuscular electrical stimulation as a revolutionary treatment option for individuals with mild obstructive sleep apnea," states Mujtaba Chohan, Head of Finance & Chief of Staff at Signifier.

MB2 Dental Enters West Virginia; New Dental Practice Partnership Marks 40th State in Which It Operates

Retrieved on: 
Wednesday, February 28, 2024
Dental, Health, Dentist, DPO, Virginia Avenue, DRS, MB2, Patient, Partnership, Dentistry

The practice, Drs. Daniel K. Monday & Stephen P. Graziani P.L.L.C., is the latest addition to MB2 Dental’s fast-growing DPO network. The two practices in the state -- one located at 1213 Virginia Street E, Charleston, WV, 25301, and another at 2939 Virginia Avenue, Hurricane, WV, 25526 -- are focused on providing general dentistry while also offering a wide array of other services, including implant placement surgery, emergency extractions and bone grafting. Dr. Monday has been in the practice since 1994 while Dr. Graziani joined in 2014.

Key Points: 
  • MB2 Dental , the first and largest Dental Partnership Organization (DPO) nationwide, announced today its entry into West Virginia with the forging of a dental partnership with two locations in the state.
  • This marks the 40th state in which MB2 Dental now operates.
  • Monday and Graziani marks a significant milestone for MB2 Dental as we expand our presence into an additional state, bringing our total to 40 nationwide.
  • We look forward to continuing to attract more doctor partners in West Virginia and are committed to further broadening MB2 Dental's impact across the state.”